Literature DB >> 15238072

Current gene-mapping strategies in experimental models of multiple sclerosis.

K Becanovic1, M Jagodic, E Wallström, T Olsson.   

Abstract

Both family-based linkage analyses and population-based association studies have failed to identify disease-regulatory non-human leucocyte antigen genes of importance in multiple sclerosis (MS). Instead, investigators have employed experimental models, which offer major advantages in genetic studies. We summarize the current main methodologies used and the status of both the human and experimental approaches. Why is it important to find genes regulating MS? There is an immense number of cellular and molecular interactions defined in the immunological field and it is very difficult to unravel those that are critical to an inflammatory disease, such as MS, by classical hypothesis-driven research. Unbiased genetics defines evolutionary conserved gene polymorphisms and pathways regulated by these genes, which are central in the pathogenesis. These, in turn, are of interest as therapeutic targets and pharmacogenetic markers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238072     DOI: 10.1111/j.0300-9475.2004.01462.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  3 in total

1.  Definition of a 1.06-Mb region linked to neuroinflammation in humans, rats and mice.

Authors:  Johan Ockinger; Pablo Serrano-Fernández; Steffen Möller; Saleh M Ibrahim; Tomas Olsson; Maja Jagodic
Journal:  Genetics       Date:  2006-04-19       Impact factor: 4.562

2.  Eae19, a new locus on rat chromosome 15 regulating experimental autoimmune encephalomyelitis.

Authors:  Jian Rong Sheng; Maja Jagodic; Ingrid Dahlman; Kristina Becanovic; Rita Nohra; Monica Marta; Ellen Iacobaeus; Tomas Olsson; Erik Wallström
Journal:  Genetics       Date:  2005-02-16       Impact factor: 4.562

3.  Fine mapping of gene regions regulating neurodegeneration.

Authors:  Maria Swanberg; Karin Harnesk; Mikael Ström; Margarita Diez; Olle Lidman; Fredrik Piehl
Journal:  PLoS One       Date:  2009-06-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.